@article{ca1ab6eaeb044835ac4902bd5b415844,
title = "Mortality risk in current and new antipsychotic Alzheimer's disease users: Large scale Japanese study",
abstract = "Introduction We studied the mortality risk of long term and new antipsychotic drug use in Alzheimer's disease (AD) patients in Japan to determine improved treatment protocols. Methods This 24-week prospective cohort study included 10,079 Japanese AD patients (female, 69%; average age, 81 years) under routine clinical care in 357 medical sites. The antipsychotic medication history was varied (63.7% were long-term users). Mortality rates and odds ratio were analyzed (initial 10 weeks and from 11–24 weeks). Results The antipsychotic exposed group with shorter treatment periods had a higher mortality risk compared to controls. The newly prescribed users (antipsychotic treatment started during the follow-up) showed increased mortality (9.4% during the 11–24 week period). Conclusions New use of antipsychotic drugs represents a distinct risk for mortality; those on long-term antipsychotic therapy seem to be at less risk. The warning issued 10 years earlier on antipsychotics use for AD patients should be reviewed.",
keywords = "Alzheimer's disease, Antipsychotics, Dementia, Mortality risk, Prospective cohort study",
author = "Heii Arai and Yu Nakamura and Masamoto Taguchi and Hiroyuki Kobayashi and Keita Yamauchi and Schneider, {Lon S.}",
note = "Funding Information: H.A. has received compensation for consulting and serving on a scientific advisory board or speaking at medical conferences from Otsuka, Eisai, MSD, Daiichi-Sankyo, Novartis, Yoshitomi, Pfizer, Janssen, MSD, Ono, Shionogi, Sawai, and NihonChemiphar and has received research funding from Otsuka, Eisai, MSD, Daiichi-Sankyo, Mochida, Tanabe-Mitsubishi, GlaxoSmithKline, Novartis, Astellas, Dainippon-Sumitomo, Yoshitomi, Pfizer, Janssen, Takeda and Lilly. Y.N. reports grants and personal fees from Daiichi-Sankyo, personal fees from Astellas, grants and personal fees from Eisai, personal fees from Mitsubishi-Tanabe, grants and personal fees from Ono, grants and personal fees from Pfizer, personal fees from Mochida, personal fees from Meiji, grants and personal fees from Janssen, grants and personal fees from MSD, personal fees from GSK, personal fees from Merz, grants and personal fees from Novartis, personal fees from AbbVie, personal fees from Boehringer Ingelheim, personal fees from Toyama-chemical, personal fees from Fuji Film RI, personal fees from Kowa, grants and personal fees from Dainihon-Sumitomo, grants and personal fees from Takeda, personal fees from Otsuka, personal fees from Astra Zeneca, personal fees from Eli Lilly, grants from Ministry of Education, Culture, Sports, Science and Technology of Japan, grants from New Energy and Industrial Technology Development Organization of Japan, outside the submitted work. M.T. reports nothing to disclose. H.K. has been a full employee of Otsuka Pharmaceutical Co., Ltd. in Japan since 2012. K.Y. reports personal fees from Otsuka during the conduct of the study. L.S.S. reports, from 3 years before and during the course of this study, receipt of grants and clinical trials support from NIH, Abbott, AstraZeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Lundbeck, Merck, Novartis, Pfizer, Roche; paid consultancy, including data monitoring committees, adjudication committees, for Abbott, AbbVie, AC Immune, AstraZeneca, Baxter, Bristol Myers Squibb, Elan, Eli Lilly, Forest Laboratories, Forum, GlaxoSmithKline, Johnson & Johnson, Lundbeck, Merck, Merz, Novartis, Orion, Otsuka, Pfizer, Roche, Servier, Takeda, Toyama/FujiFilm, Zinfandel. Publisher Copyright: {\textcopyright} 2016 The Alzheimer's Association",
year = "2016",
month = jul,
day = "1",
doi = "10.1016/j.jalz.2016.03.006",
language = "English",
volume = "12",
pages = "823--830",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "7",
}
